- Home
- KZIA vs GSIW Comparison
KZIA vs GSIW Comparison
Compare KZIA & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- GSIW
- Stock Information
- Founded
- KZIA 1994
- GSIW 2016
- Country
- KZIA Australia
- GSIW Hong Kong
- Employees
- KZIA N/A
- GSIW N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- GSIW
- Sector
- KZIA Health Care
- GSIW
- Exchange
- KZIA Nasdaq
- GSIW Nasdaq
- Market Cap
- KZIA 7.8M
- GSIW 8.6M
- IPO Year
- KZIA 1999
- GSIW 2023
- Fundamental
- Price
- KZIA $1.42
- GSIW $0.65
- Analyst Decision
- KZIA Strong Buy
- GSIW
- Analyst Count
- KZIA 1
- GSIW 0
- Target Price
- KZIA $20.00
- GSIW N/A
- AVG Volume (30 Days)
- KZIA 116.4K
- GSIW 187.0K
- Earning Date
- KZIA 11-15-2024
- GSIW 12-31-2024
- Dividend Yield
- KZIA N/A
- GSIW N/A
- EPS Growth
- KZIA N/A
- GSIW N/A
- EPS
- KZIA N/A
- GSIW N/A
- Revenue
- KZIA $1,655,324.00
- GSIW $1,408,469.00
- Revenue This Year
- KZIA $806.89
- GSIW N/A
- Revenue Next Year
- KZIA N/A
- GSIW N/A
- P/E Ratio
- KZIA N/A
- GSIW N/A
- Revenue Growth
- KZIA 248000.00
- GSIW N/A
- 52 Week Low
- KZIA $1.39
- GSIW $0.52
- 52 Week High
- KZIA $15.80
- GSIW $15.99
- Technical
- Relative Strength Index (RSI)
- KZIA 20.74
- GSIW 49.06
- Support Level
- KZIA $1.42
- GSIW $0.55
- Resistance Level
- KZIA $1.89
- GSIW $0.69
- Average True Range (ATR)
- KZIA 0.24
- GSIW 0.07
- MACD
- KZIA 0.02
- GSIW 0.02
- Stochastic Oscillator
- KZIA 1.40
- GSIW 56.55
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.